Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
A total of 103 regained 50% to 75%
the course may be repeated
doi: 10.1038/s41580-020-00324-8 130 RatliffBBAbdulmahdiWPawarRWolinMS
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients
Forward-looking statements in this news release include, but are not limited to, statements regarding the development, advancement, regulatory pathway, and potential commercialization of BNT23001, the Company's patented sublingual Cladribine orally dissolvable film ("ODF") program for multiple sclerosis
US$ 20.24
US$ 22.01
US$ 28.40
US$ 21.54
US$ 20.86
US$ 27.19
US$ 29.02
US$ 26.79
